AIFinancial Timesabout 15 hours ago
Tempus to Acquire Personalis
1 min read
Tempus announced plans to acquire Personalis, integrating molecular residual disease (MRD) testing into its AI-enabled precision oncology platform. The deal aims to combine Tempus's AI capabilities with Personalis's MRD technology for cancer care. Financial terms were not disclosed.
Level
Hype check
Tap to vote and see what everyone thinks.
